PortalPublikationenPrognostic effect of low-level HER2 expression in patients w...

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

Standard

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. / Hein, Alexander; Hartkopf, Andreas D; Emons, Julius; Lux, Michael P; Volz, Bernhard; Taran, Florin-Andrei; Overkamp, Friedrich; Hadji, Peyman; Tesch, Hans; Häberle, Lothar; Ettl, Johannes; Lüftner, Diana; Wurmthaler, Lena A; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Wimberger, Pauline; Hielscher, Carsten; Kurbacher, Christian M; Wuerstlein, Rachel; Thomssen, Christoph; Untch, Michael; Fasching, Peter A; Janni, Wolfgang; Fehm, Tanja N; Wallwiener, Diethelm; Brucker, Sara Y; Schneeweiss, Andreas; Kolberg, Hans-Christian.

in: EUR J CANCER, Jahrgang 155, 09.2021, S. 1-12.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hein, A, Hartkopf, AD, Emons, J, Lux, MP, Volz, B, Taran, F-A, Overkamp, F, Hadji, P, Tesch, H, Häberle, L, Ettl, J, Lüftner, D, Wurmthaler, LA, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Kurbacher, CM, Wuerstlein, R, Thomssen, C, Untch, M, Fasching, PA, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY, Schneeweiss, A & Kolberg, H-C 2021, 'Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status', EUR J CANCER, Jg. 155, S. 1-12. https://doi.org/10.1016/j.ejca.2021.06.033

APA

Hein, A., Hartkopf, A. D., Emons, J., Lux, M. P., Volz, B., Taran, F-A., Overkamp, F., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wurmthaler, L. A., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wimberger, P., Hielscher, C., ... Kolberg, H-C. (2021). Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. EUR J CANCER, 155, 1-12. https://doi.org/10.1016/j.ejca.2021.06.033

Vancouver

Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran F-A et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. EUR J CANCER. 2021 Sep;155:1-12. https://doi.org/10.1016/j.ejca.2021.06.033

Bibtex

@article{273aa9ff34a447a3ace8e04391e22de1,
title = "Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status",
abstract = "PURPOSE: Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates for novel therapies targeting HER2. This study aimed to assess tumour and patient characteristics and prognosis in patients with advanced breast cancer (aBC), relative to low HER2 expression levels.METHODS: PRAEGNANT is a prospective aBC registry (NCT02338167), focusing on molecular biomarkers. Patients in all therapy lines receiving any kind of treatment are eligible. This analysis includes patients with conventionally HER2-negative aBC. Clinical outcome was compared in the groups with no (IHC score 0) or with low HER2 expression (IHC 1+, or IHC 2+/ISH negative).RESULTS: Low HER2 expression levels in triple-negative aBC patients did not influence progression-free survival. Overall survival appeared poorer in patients with IHC 2+ compared with patients with no HER2 expression in the unadjusted analysis (hazard ratio 2.24, 95% confidence interval 0.1.12-4.47). However, this effect was not maintained in the adjusted analysis. In HER2-negative, hormone receptor-positive patients, low HER2 expression appeared to have no effect on prognosis, neither progression-free survival nor overall survival.CONCLUSIONS: We could not demonstrate that HER2 expression at a low level and assessed in clinical routine can differentiate patients into prognostic groups. However, the prevalence of patients with a low expression makes this population interesting for clinical trials with potentially active treatments using HER2 as a target.",
author = "Alexander Hein and Hartkopf, {Andreas D} and Julius Emons and Lux, {Michael P} and Bernhard Volz and Florin-Andrei Taran and Friedrich Overkamp and Peyman Hadji and Hans Tesch and Lothar H{\"a}berle and Johannes Ettl and Diana L{\"u}ftner and Wurmthaler, {Lena A} and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W} and Erik Belleville and Pauline Wimberger and Carsten Hielscher and Kurbacher, {Christian M} and Rachel Wuerstlein and Christoph Thomssen and Michael Untch and Fasching, {Peter A} and Wolfgang Janni and Fehm, {Tanja N} and Diethelm Wallwiener and Brucker, {Sara Y} and Andreas Schneeweiss and Hans-Christian Kolberg",
note = "Copyright {\textcopyright} 2021 Elsevier Ltd. All rights reserved.",
year = "2021",
month = sep,
doi = "10.1016/j.ejca.2021.06.033",
language = "English",
volume = "155",
pages = "1--12",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

AU - Hein, Alexander

AU - Hartkopf, Andreas D

AU - Emons, Julius

AU - Lux, Michael P

AU - Volz, Bernhard

AU - Taran, Florin-Andrei

AU - Overkamp, Friedrich

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Häberle, Lothar

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Wurmthaler, Lena A

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Wimberger, Pauline

AU - Hielscher, Carsten

AU - Kurbacher, Christian M

AU - Wuerstlein, Rachel

AU - Thomssen, Christoph

AU - Untch, Michael

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Fehm, Tanja N

AU - Wallwiener, Diethelm

AU - Brucker, Sara Y

AU - Schneeweiss, Andreas

AU - Kolberg, Hans-Christian

N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.

PY - 2021/9

Y1 - 2021/9

N2 - PURPOSE: Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates for novel therapies targeting HER2. This study aimed to assess tumour and patient characteristics and prognosis in patients with advanced breast cancer (aBC), relative to low HER2 expression levels.METHODS: PRAEGNANT is a prospective aBC registry (NCT02338167), focusing on molecular biomarkers. Patients in all therapy lines receiving any kind of treatment are eligible. This analysis includes patients with conventionally HER2-negative aBC. Clinical outcome was compared in the groups with no (IHC score 0) or with low HER2 expression (IHC 1+, or IHC 2+/ISH negative).RESULTS: Low HER2 expression levels in triple-negative aBC patients did not influence progression-free survival. Overall survival appeared poorer in patients with IHC 2+ compared with patients with no HER2 expression in the unadjusted analysis (hazard ratio 2.24, 95% confidence interval 0.1.12-4.47). However, this effect was not maintained in the adjusted analysis. In HER2-negative, hormone receptor-positive patients, low HER2 expression appeared to have no effect on prognosis, neither progression-free survival nor overall survival.CONCLUSIONS: We could not demonstrate that HER2 expression at a low level and assessed in clinical routine can differentiate patients into prognostic groups. However, the prevalence of patients with a low expression makes this population interesting for clinical trials with potentially active treatments using HER2 as a target.

AB - PURPOSE: Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates for novel therapies targeting HER2. This study aimed to assess tumour and patient characteristics and prognosis in patients with advanced breast cancer (aBC), relative to low HER2 expression levels.METHODS: PRAEGNANT is a prospective aBC registry (NCT02338167), focusing on molecular biomarkers. Patients in all therapy lines receiving any kind of treatment are eligible. This analysis includes patients with conventionally HER2-negative aBC. Clinical outcome was compared in the groups with no (IHC score 0) or with low HER2 expression (IHC 1+, or IHC 2+/ISH negative).RESULTS: Low HER2 expression levels in triple-negative aBC patients did not influence progression-free survival. Overall survival appeared poorer in patients with IHC 2+ compared with patients with no HER2 expression in the unadjusted analysis (hazard ratio 2.24, 95% confidence interval 0.1.12-4.47). However, this effect was not maintained in the adjusted analysis. In HER2-negative, hormone receptor-positive patients, low HER2 expression appeared to have no effect on prognosis, neither progression-free survival nor overall survival.CONCLUSIONS: We could not demonstrate that HER2 expression at a low level and assessed in clinical routine can differentiate patients into prognostic groups. However, the prevalence of patients with a low expression makes this population interesting for clinical trials with potentially active treatments using HER2 as a target.

U2 - 10.1016/j.ejca.2021.06.033

DO - 10.1016/j.ejca.2021.06.033

M3 - SCORING: Journal article

C2 - 34311211

VL - 155

SP - 1

EP - 12

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -